Positive long-term data from Phase II stroke disability clinical trial accepted for a late-breaking podium presentation at the American Heart Association International Stroke Conference 2018
Positive long-term data from Phase II stroke disability clinical trial accepted for a late-breaking podium presentation at the American Heart Association International Stroke Conference 2018
To view the full article click here…
Long term data from Phase II stroke clinical trial confirm positive results seen after three months.
To view the full article click here…
5th June 2017: ReNeuron Group plc (the “Company”) (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to provide a further update regarding its US clinical and regulatory development strategy for its CTX cell therapy candidate for stroke disability.
To view the full article click here…
21st April 2017: ReNeuron Group plc (the “Company”) (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to provide an update on its CTX-based cell therapy development programmes.
ReNeuron’s CTX cell therapy candidate has been featured in the BBC documentary, “Andrew Marr: My Brain and Me”, which was screened for the first time on 14 February 2017 on BBC2.
15 February 2017: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that its CTX cell therapy candidate has been featured in the BBC documentary, “Andrew Marr: My Brain and Me”, which was screened for the first time last night on BBC2.